To view the fulltext, please log in
To view the pdf, please log in
The human gastrointestinal tract is colonized by 100 trillion microorganisms, including both beneficial and potentially pathogenic species. A zwitterionic polysaccharide (PSA) from the gastrointestinal microorganism Bacteroides fragilis has been shown to be the archetypal molecule of commensal bacteria that mediates development of the host immune system. PSA stimulates the normal balance of Th1 and Th2 CD4+ T cells and can correct histologic defects in the spleen and thymus of germ-free mice. PSA stimulates the innate immune system as a ligand for Toll-like receptor 2 and thereby promotes interactions with the adaptive immune system that are required for T-cell activation. PSA protects animals from colitis induced by Helicobacter hepaticus, a commensal with pathogenic potential. In animals harboring a B. fragilis mutant that does not express PSA, H. hepaticus colonization leads to disease and proinflammatory cytokine production in colonic tissues. Purified PSA administered to animals suppresses the production of the proinflammatory cytokine interleukin-17 by intestinal immune cells. PSA protects animals from inflammatory disease through a functional requirement for interleukin-10-producing CD4+ T cells. Thus polysaccharides of the bacterial microbiota can mediate the critical balance between health and disease in the host. As evidence accumulates, this concept is being accepted as an important feature of the immune repertoire.
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Hooper LV, Gordon JI: Commensal host-bacterial relationships in the gut. Science 2001;292:1115-1118
- Krinos CM, Coyne MJ, Weinacht KG, et al: Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature 2001;414:555-558
- Baumann H, Tzianabos AO, Brisson JR, et al: Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry 1992;31:4081-4089
- Comstock LE, Kasper DL: Bacterial glycans: key mediators of diverse host immune responses. Cell 2006;126:847-850
- Tzianabos AO, Finberg RW, Wang Y, et al: T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem 2000;275:6733-6740
- Abbas AK, Lichtman AH, Pober JS: Cellular and Molecular Immunology. 4New York, Saunders, 2000;
- Mazmanian SK, Kasper DL: The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol 2006;6:849-858
- Cobb BA, Wang Q, Tzianabos AO, Kasper DL: Polysaccharide processing and presentation by the MHCII pathway. Cell 2004;117:677-687
- Duan J, Avci FY, Kasper DL: Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway. Proc Natl Acad Sci USA 2008;105:5183-5188
- Cobb BA, Kasper DL: Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. Glycobiology 2008;18:707-717
- Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL: An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-118
- Mazmanian SK, Round JL, Kasper DL: A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625
- Wang Q, McLoughlin RM, Cobb BA, et al: A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med 2006;203:2853-2863
- Powrie F, Read S, Mottet C, et al: Control of immune pathology by regulatory T cells. Novartis Found Symp 2003;252:92-114
- Ruiz-Perez B, Chung DR, Sharpe AH, et al: Modulation of surgical fibrosis by microbial zwitterionic polysaccharides. Proc Natl Acad Sci USA 2005;102:16753-16758
- Gerding DN, Johnson S: Clostridium difficile-associated disease, including pseudomembranous colitis. (eds) Fauci AS, Braunwald E, Kasper DL, et al: Harrison's Principles of Internal Medicine 17New York, McGraw-Hill, 2008;818-821
- Strachan DP: Hay fever, hygiene, and household size. BMJ 1989;299:1259-1260
- Bjorksten B, Naaber P, Sepp E, Mikelsaar M: The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999;29:342-346
- Kirjavainen PV, Apostolou E, Arvola T, et al: Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol Med Microbiol 2001;32:1-7
- Kalliomäki M, Kirjavainen P, Eerola E, et al: Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129-134